3.650USD-1.08%Mkt Cap: 595.15M USDP/E: —Last update: 2026-05-22
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabt…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap595.15M USD
Enterprise Value511.49M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-167.86M USD
Revenue/Share—
Last Price3.650 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees154
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.51
PEG—
EV/EBITDA-2.88
EV/Revenue—
P/S—
P/B3.98
EPS (TTM)-1.78
EPS (Forward)-1.47
52W Range
1.26080% of range4.230
52W High4.230 USD
52W Low1.260 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-149.80%
ROA-101.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-131.08M USD
CapEx (TTM)1.23M USD
FCF Margin—
FCF Yield-15.28%
Net Debt-90.19M USD
Net Debt/EBITDA0.51
Balance Sheet
Debt/Equity0.24
Current Ratio2.95
Quick Ratio2.81
Book Value/Sh0.9280 USD
Cash/Share0.7150 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)13.38 USD
Target Range4.000 USD – 30.00 USD
# Analysts8
Ownership
Shares Out.163.05M
Float142.90M
Insiders0.99%
Institutions54.24%
Short Interest
Short Ratio10.4d
Short % Float21.58%
Short % Out.18.53%
Shares Short20.63M
Short (prev mo.)19.97M
Technical
SMA 503.194 (+14.3%)
SMA 2002.584 (+41.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)4.05M
Avg Vol (10d)3.85M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—